Source comparison
TB-500 Loading Dose Protocol Front-Loading: Comparison
| Protocol Type | Loading Phase Dose | Loading Phase Duration | Time to Therapeutic Tissue Concentration | Total Dose (First 6 Weeks) | Ideal Use Case | Professional Assessment ||—|—|—|—|—|—|| Front-Loading (Aggressive) | 10mg every 3 days | 14 days | 48–72 ho
This comparison does not assign a generated winner or score.
- | Protocol Type | Loading Phase Dose | Loading Phase Duration | Time to Therapeutic Tissue Concentration | Total Dose (First 6 Weeks) | Ideal Use Case | Professional Assessment ||—|—|—|—|—|—|| Front-Loading (Aggressive) | 10mg every 3 days | 14 days | 48–72 hours | 40–50mg | Acute injury, post-surgical recovery, large tissue damage | Fastest receptor saturation; highest cost; requires precise timing and storage discipline || Front-Loading (Standard) | 5mg every 3–4 days | 7–10 days | 72–96 hours | 30–40mg | Localized injuries (single joint/tendon), moderate inflammation | Balances speed and cost; most common in research settings || Standard Weekly Dosing | 2–3mg weekly | No loading phase | 21–28 days | 12–18mg | Chronic inflammation, long-term tissue health, prevention protocols | Slower accumulation; lower cost; suitable when repair window is not time-sensitive || Micro-Dosing | 1–2mg 2–3x/week | No loading phase | 14–21 days | 15–20mg | Maintenance after loading phase, low-grade chro
- The comparison shows why front-loading exists as a distinct strategy rather than simply "more TB-500." Doubling the weekly dose from 2mg to 4mg does not create the same tissue kinetics as administering 5mg every 3 days. The peak-to-trough variation changes receptor occupancy patterns, and higher peaks drive more aggressive cellular migration during the acute window.